66.7 F
Laguna Hills
Thursday, Oct 6, 2022
-Advertisement-

DAVID MOATAZEDI

CEO, President, Evolus


WHY:
Nearly $500M-valued company has one of the first neurotoxins that competes with Botox on the commercial market. Previously at Allergan for 14 years as senior VP of Medical Aesthetics division.

RECENT: Initial product Jeuveau, designed to act similarly to Botox but at a lower cost in treating moderate to severe frown lines, got FDA approval in February; had sales kick off in late June.


NOTABLE:
Evolus is indirectly involved in a lawsuit with Allergan due to Korean manufacturer of its products, Allergan claims intellectual infringement.


FUN FACTS:
Three kids: Sienna, Gavin, and Pierce; favorite book, “Pillars of the Earth.”

Return to List

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-